55,562 Shares in Humana Inc. (NYSE:HUM) Purchased by Proficio Capital Partners LLC

Proficio Capital Partners LLC acquired a new position in shares of Humana Inc. (NYSE:HUM) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 55,562 shares of the insurance provider’s stock, valued at approximately $14,097,000.

Several other hedge funds have also added to or reduced their stakes in the stock. State Street Corp raised its holdings in shares of Humana by 1.0% in the 3rd quarter. State Street Corp now owns 5,357,420 shares of the insurance provider’s stock worth $1,701,582,000 after purchasing an additional 53,272 shares during the period. FMR LLC raised its stake in shares of Humana by 23.4% in the third quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock valued at $1,073,387,000 after buying an additional 643,291 shares during the period. Pzena Investment Management LLC lifted its position in shares of Humana by 8.1% during the 3rd quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock valued at $793,830,000 after buying an additional 187,903 shares during the last quarter. Ontario Teachers Pension Plan Board grew its stake in shares of Humana by 6.5% during the 3rd quarter. Ontario Teachers Pension Plan Board now owns 1,173,535 shares of the insurance provider’s stock worth $371,705,000 after acquiring an additional 71,910 shares during the period. Finally, Sanders Capital LLC increased its holdings in Humana by 1.0% in the 3rd quarter. Sanders Capital LLC now owns 1,168,341 shares of the insurance provider’s stock worth $370,060,000 after acquiring an additional 11,923 shares during the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Price Performance

Shares of NYSE:HUM opened at $270.91 on Friday. The company’s fifty day moving average price is $271.11 and its 200-day moving average price is $286.85. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. The firm has a market capitalization of $32.68 billion, a price-to-earnings ratio of 27.23, a PEG ratio of 2.05 and a beta of 0.56. Humana Inc. has a one year low of $213.31 and a one year high of $406.46.

Humana (NYSE:HUM) last released its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, equities research analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a $0.885 dividend. This represents a $3.54 annualized dividend and a yield of 1.31%. The ex-dividend date is Friday, March 28th. Humana’s dividend payout ratio is currently 35.58%.

Insider Buying and Selling at Humana

In other news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This represents a 31.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.32% of the company’s stock.

Wall Street Analysts Forecast Growth

HUM has been the subject of a number of research reports. Bank of America upgraded shares of Humana from an “underperform” rating to a “neutral” rating and increased their target price for the stock from $247.00 to $308.00 in a research report on Wednesday, November 6th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $290.00 price objective on shares of Humana in a report on Wednesday, February 12th. JPMorgan Chase & Co. lowered their target price on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a report on Tuesday, February 18th. Barclays raised their price target on Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a report on Thursday, February 13th. Finally, Truist Financial boosted their price objective on Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research note on Monday, January 6th. Nineteen investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $285.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.